Les Tari
Chief Tech/Sci/R&D Officer at CIDARA THERAPEUTICS, INC.
Net worth: 241 423 $ as of 2024-04-29
Les Tari active positions
Companies | Position | Start | End |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-02-28 | - |
Corporate Officer/Principal | 2014-06-30 | 2019-02-28 |
Career history of Les Tari
Former positions of Les Tari
Companies | Position | Start | End |
---|---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2007-02-28 | 2014-02-28 |
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Founder | 2002-12-31 | 2006-12-31 |
Corporate Officer/Principal | 2002-12-31 | 2006-12-31 | |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 2000-12-31 | 2002-12-31 |
Training of Les Tari
University of Manitoba | Doctorate Degree |
Statistics
International
United States | 5 |
Canada | 2 |
Operational
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Distribution Services |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Les Tari
- Experience